is provided
• The definition of obesity requires anthropometric and clinical descriptors • The diagnosis and management of obesity requires a process of screening, evaluation of complications (using checklist), staging, and algorithmic management • This advanced framework has been approved by AACE and will be distributed to the wide array of stakeholders who attended the CCO for structured discussion and creation of a consensus diagnosis that is broadly actionable
THE PURPOSE AND MANDATE FOR A NEW DIAGNOSTIC APPROACH TO OBESITY
The 2014 American Association of Clinical Endocrinologists and the American College of Endocrinology (AACE/ACE) Consensus Conference on Obesity (CCO) was convened to establish an evidence base that could be used to develop a comprehensive plan to combat obesity. The Conference involved a wide array of national stakeholders (the "Pillars") with a vested interest in obesity, whose concerted participation would be necessary to support an effective overall action plan. A key consensus concept that emerged from the Conference was that a more medically meaningful and actionable definition of obesity was needed. It became clear that the diagnosis based solely on anthropometric measures (e.g., body mass index [BMI] ) lacked information needed for concerted action among healthcare professionals, healthcare systems, regulators, payers, and employers. Furthermore, the elements for an improved diagnosis should include both the anthropometric criterion together with an indication of the degree to which the weight gain was negatively impacting the health of individual patients.
This document addresses this problem of diagnostic uncertainty and is the first step in removing this impediment for concerted and comprehensive action. This advanced framework (Table 1) for a new diagnosis of obesity as a chronic disease translates the emergent concept from the AACE CCO into an actionable recommendation. Because concerted action will be necessary, this framework will be submitted to our Pillar partners for comment and recommendations. With our partners, we will explore new terminology to improve communication and implementation, develop a new diagnostic algorithm that is mapped to evidence-based risk-stratified patient subsets, and apply the AACE/ACE complications-centric obesity management algorithm. This document has been approved by the AACE/ACE Board of Directors and will be distributed to the 2014 CCO Pillar representatives with a structured questionnaire for comments. The goal will be to achieve consensus for a medically meaningful and actionable diagnosis of obesity that will support access to rationally delivered interventions for obesity prevention and treatment.
THE DIAGNOSIS OF OBESITY
A new definition and diagnostic strategy for obesity is required that is actionable, medically meaningful, and adds value to the health-promoting effects of weight loss. The AACE/ACE defines obesity as a chronic disease characterized by pathophysiological processes that result in increased adipose tissue mass and which can result in increased morbidity and mortality. In an environment that interacts with susceptibility genes to promote weight gain The diagnosis facilitates another mandate of the CCO that a comprehensive action plan to combat obesity must include primary, secondary, and tertiary disease interventions. If the BMI is <25 kg/m 2 (and waist circumference is not increased), these patients have normal weights and are candidates for primary interventions to prevent obesity, perhaps through healthy lifestyle education and reductions in the obesogenic nature of their environment. If the patients are overweight or obese and have no complications (Stage 0), they are eligible for secondary interventions to prevent progressive weight gain and the emergence of obesity-related complications. Once complications develop, whether individuals are overweight or obese, it has become clear that the increase in body weight is adversely affecting the health of the individual, and tertiary interventions are required to prevent worsening of the disease and to treat the complications. Thus, all patients with BMI ≥25 kg/m 2 and obesity-related complications require tertiary interventions, and have Obesity Stage 1 if mild-moderate (but no severe) complications are present and Obesity Stage 2 if severe complications are present. The identification and staging of obesity-related complications is based on complication-specific criteria. Table 2 illustrates the Advanced Framework to incorporate the principles of primary, secondary, and tertiary interventions and treatment.
The new diagnosis aligns itself with a 4-step approach for the evaluation of patients with obesity, and entrains professionals by providing them with a structured paradigm for patient management consistent with high-quality care. The 4 recommended steps are: 1) screening with BMI with adjustments for ethnic differences, 2) clinical evaluation for the presence of obesity-related complications using a checklist, 3) staging for the severity of complications using complication-specific criteria, and 4) selection of prevention and/or intervention strategies targeting specific complications as guided by the AACE/ACE obesity management algorithm. These recommendations have been translated from concepts and evidence derived from the AACE/ACE CCO on March 23-24, 2014 in Washington, DC (2) .
RATIONALE, PRINCIPLES, AND DEVELOPMENT OF THE DIAGNOSTIC APPROACH
The 2014 AACE/ACE CCO The 2014 AACE/ACE CCO was predicated on a belief that concerted action among a diverse array of stakeholders is required for significant reduction in obesity prevalence rates. The Conference convened March 23 and 24, 2014 in Washington, DC, and resulted in a portfolio of "affirmed concepts" (ACs) representing the validation of previously held concepts and practices, and "emergent concepts" (ECs) that became apparent only through the vigorous analyses and discussions emanating from the multidisciplinary cohort of attendees that included insights from health care professionals, government/regulatory entities, pharmaceutical industry, large employers, large payers, lay and professional organizations, educational organizations, and research sponsors (2) . The principal finding, reflected in EC.1, was that the diagnostic definition of obesity needs to be improved. The justification for this is that conference participants, representing a broad base of stakeholders in the American healthcare system with a vested interest in the problem of obesity, identified the current definition as a major obstacle to concerted action. Despite the paradigm shift suggested by increased numbers of organizations recognizing obesity as a chronic disease, the diagnosis of obesity has not changed. The old diagnosis primarily relied on the anthropomorphic measure of BMI (3, 4) , with uncertainties regarding how an increase in BMI affects individual health. AACE/ACE has developed a new definition and diagnostic algorithm, which is actionable and medically meaningful, and represents a translation of the findings of the CCO. The lack of a medically meaningful strategy and poor translation of accumulating scientific data regarding the pathogenesis of obesity as a chronic disease have also limited the effectiveness of public health initiatives.
Rationale and Underlying Principles
This new strategy is based upon current scientific evidence indicating that the pathogenesis of obesity conforms to the chronic disease model; that is, a disease that arises from the interaction of susceptibility genes, environment, and behavior with overlapping or additional subsets of gene-environment interactions determining disease severity, health impacts, and complication development. The S t e p 1 • May need therapy specific for complications 1 . Following weight loss as a result of therapy in Step 4, obesity-related complications should be re-evaluated. If the complications have not been treated to target, then weight loss therapy needs to be intensified and/or complication-specific interventions should be employed. 2. Obesity is a chronic disease and the diagnostic categories for obesity may not be static. Therefore, patients require ongoing follow-up, re-evaluation, and long term treatment. new strategy addresses these issues and specifically incorporates the following attributes of an obesity chronic disease model:
• Obesity as a chronic disease (5);
• Obesity results from the complex interaction of multiple biological factors (e.g., susceptibility genes), environmental factors (e.g., built environment), and behavior; • High prevalence rates and an obesogenic environment place a majority of individuals in many societies at some level of risk; therefore, all individuals must be screened; • Screening should include BMI but not exclude other measures that more directly quantify adipose tissue mass, in a preventive care model, including adjustments for ethnic differences in risk thresholds and modifiers to account for epidemiological, behavioral, and physiological differences among individuals; • The diagnosis of obesity prioritizes organ dysfunction resulting in discernible complications as a marker of disease and disease severity; • A complication-centric approach to management will target increasingly aggressive therapeutic approaches to those patients with obesity-related complications who will most benefit from treatment, thus optimizing patient outcomes, benefit/risk ratio of intervention, and cost effectiveness (1,6); • There is an emphasis on obesity-related complications that can be ameliorated by weight-loss therapy; • The diagnosis appropriately designates individuals appropriate for primary, secondary, and tertiary interventions for prevention and treatment; • Screening, diagnosis, and staging are relevant to management options, as directed by the AACE/ACE Obesity Algorithm (1), which treats complications as the end point of weight loss therapy, not BMI
Development of the Diagnostic Approach: Questions to be Vetted by Pillar Partners
The new obesity diagnosis will require input from multiple stakeholders to assure broad-based acceptance and concerted action in a comprehensive plan to combat obesity. Therefore, our pillar participants will be asked for feedback. Some questions requiring vetting are included below. a. Improvements in the Advanced Framework. Are there improvements needed in the diagnosis to better indicate what we are treating and why are we treating it? b. Alternative medical term other than "obesity." The term obesity has been widely used in multiple contexts and conveys a sense of stigmatization for patients. Do we need new terminology when approaching the prevention and treatment of this disease and its complications from a clinical perspective? Should consideration be given to renaming the chronic disease state in a format that effectively reflects the concept of weightdriven disease, for example "adiposity-based chronic disease (ABCD)"; this concept is consistent with the use of alternative diagnostic labels for diseases identified by eponyms, popular references, or antiquated terminology ("obesity" derived from obesitas, obdere, or ob + edere all meaning "fatness" or "to overeat" and not reflecting a pathophysiology should be employed to identify individuals with high risk for obesity based on fat mass with attention to gender differences in body composition.
1.5 Individuals who meet the anthropometric criterion for the diagnosis of overweight or obesity would then be evaluated for obesity-related complications (i.e., the clinical criterion that constitutes the second component of the diagnostic algorithm). In this way, the anthropometric criterion is necessary but not sufficient for a complete diagnosis, which also requires the pathophysiological component as reflected in complications or risk of complications as a marker of disease severity.
Step transaminases, in addition to assessment of diet, meal pattern preferences, and physical activity. An obesityfocused review of systems could be obtained using a form that the patient could fill out in the office or prior to the initial visit.
2.2 Diagnostic evaluation includes a stepped evaluation protocol and checklist for the presence of obesityrelated complications based on information from the initial visit, with an emphasis on those complications that can be ameliorated using weight loss therapy, as illustrated in Table 3 . The initial basic clinical evaluation is sufficient to determine whether many obesity-related complications are present or absent, or to strongly suspect their presence. In many instances, further evaluation may be necessary according to standards of care to confirm the presence of obesityrelated complications as alluded to in Step 3.
Step 3. Disease Staging and Complications-centric Approach
3.1 If any obesity-related complications are identified, individuals should undergo further evaluation to stage the severity of each complication.
3.1 In many cases, the confirmation of the presence of an obesity-related complication, and the staging of the severity of the complication, can be accomplished using the information obtained at the initial "new" patient evaluation. Other complications may require additional testing as recommended by standards of care to confirm the presence of the complication and/ or to stage the severity of the complication. Table 4 proposes criteria for staging of obesity-related complications for purposes of illustration, but, in many cases, subspecialty expertise will be required for optimization of these criteria based on data.
3.2 Staging is completed for each of the identified complications using complications-specific criteria (see Table 4 ) and staged as:
• Figure 1 , which is part of the AACE/ACE Comprehensive Diabetes Treatment Algorithm (1). Obesity management never precludes specific complication-related treatment outside of weight-loss therapy when needed. The selection of treatment modality and intensity will require clinical judgment and individualization of therapy; however, Table 5 proposes treatment approaches based on diagnostic category that would generally apply in many individuals.
Overweight and Obesity
Stage 0 are indicative of the absence of obesity-related complications. From the perspective of cardiometabolic disease, these patients have been referred to as the "healthy obese" (8, 9) , and, in this instance, biomechanical and other complications of obesity would similarly not be present. While therapy should be individualized and based on clinical decision-making, patients with Overweight/Obesity Stage 0 would generally be treated with lifestyle modification employing meal patterns that promote health (10), behavior modification, and increased physical activity primarily intended to prevent progressive weight gain and/or the emergence of complications in the future. More emphasis on weight reduction and hypocaloric diets may be warranted with BMI ≥30 or in patients with rapid increases in body weight. These individuals require interventions for the secondary phase of treatment/prevention of chronic disease. Other obesity-related complications or disease processes that could be treated with weight-loss therapy: Improvement in risk of surgery and anesthesia; idiopathic intracranial hypertension/pseudotumor cerebri; primary prevention of cancer in high-risk individuals and families; secondary prevention of breast cancer; congestive heart failure; infertility; "low testosterone"/hypogonadism; back pain; lower extremity venous stasis and edema; thrombophlebitis; prior to pregnancy to improvement in maternal/fetal outcomes; chronic lung disease, including asthma; chronic kidney disease/renal protection; reductions in quality of life.
Abbreviations: BMI = body mass index; GERD = gastroesophageal reflux disease; HbA1c = glycated hemoglobin; HDL-c = highdensity lipoprotein cholesterol; LDL-c = low-density lipoprotein cholesterol; NAFLD = nonalcoholic fatty liver disease; NASH = nonalchoholic steatohepatitis; PCOS = polycystic ovary syndrome; T2DM = type 2 diabetes mellitus a Initial evaluation in patients with obesity (BMI ≥25 kg/m 2 ) includes: history, physical examination, review of systems, blood pressure, waist circumference, fasting glucose, fasting lipid panel (total cholesterol, LDL-c, HDL-c, triglycerides), creatinine, and hepatic transaminases. 
L] Other Complications
Specific staging criteria could also be established for the following complications and other disease processes that can be prevented and/or treated using weight loss therapy:
• Idiopathic intracranial hypertension/pseudotumor cerebri; primary prevention of cancer in high-risk individuals and families; secondary prevention of breast cancer; congestive heart failure; infertility not associated with PCOS; "low testosterone"/hypogonadism; sexual function related to the mechanical aspects of coitus; back pain; lower extremity venous stasis and edema; thrombophlebitis; deep vein thrombosis; gastric ulcers; maternal/ fetal risk of pregnancy; improvement in risk of surgery and anesthesia; chronic lung disease including asthma; gout; chronic kidney disease/renal protection; poor quality of life.
Abbreviations: AHI = apnea hypopnea index; BP = blood pressure; CMDS = cardiometabolic disease stage; GERD = gastroesophageal reflux disease; HDL-c = high-density lipoprotein cholesterol; LDL-c = low-density lipoprotein cholesterol; NAFLD = nonalcoholic fatty liver disease; NASH = nonalchoholic steatohepatitis; PCOS = polycystic ovary syndrome; T2DM = type 2 diabetes mellitus; TG = triglycerides; WC = waist circumference a While there is an evidence base for the complications-specific criteria below that are used to stage the severity of obesity-related complications, several criteria may require additional expert scrutiny, critique, and research for optimization. 
Diagnosis
Complications-specific staging and treatment
Step 1
Step 2
Step 3
Step 4 Patients with increased BMI due to muscularity should be excluded. b In certain ethnic populations, waist circumference should be assessed if the BMI is 23 to 25 kg/m 2 . If the waist circumference is elevated using ethnic population-specific cutoff values, this positive risk factor identifies a patient who could benefit from weight loss and per se meets the criteria for an Obesity stage 1 diagnosis. Waist circumference is also used in the clinical evaluation of all patients for Metabolic Syndrome. c Stages are determined using criteria specific to each obesity-related complication; stage 0 = no complication; stage 1 = mild-tomoderate; stage 2 = severe. d Treatment plan should be individualized; suggested interventions are appropriate for obtaining the sufficient degree of weight loss generally required to treat the obesity-related complication(s) at the specified stage of severity. e BMI ≥27 is consistent with the prescribing information mandated by the Food and Drug Administration for weight-loss medications. 4.4 Obesity Stage 2 is indicative of the presence of 1 or more obesity-related complications that are severe based on complication-specific criteria (see Table 3 ). Stage 2 complications generally have a more adverse impact on individual health, and/or require more aggressive obesity management with a greater degree of weight loss (e.g., ≥10% weight loss) in order to effectively or optimally treat the obesity-related complication. While therapy should be individualized and based on judgment, in general, patients with Obesity Stage 2 would effectively be treated with intensive lifestyle/behavioral therapy in conjunction with a weightloss medication or bariatric surgery. Obesity Stage 2 includes both overweight and obese patients with 1 or more severe complications that can be ameliorated by weight loss. The emphasis, therefore, is on improving the patient's health and treating complications and not their BMI level per se. As indicated for Obesity Stage 1, these individuals require interventions for the tertiary phase of treatment/prevention of chronic disease.
4.5 Patients meeting the diagnosis for Obesity, whether Stage 0, 1, or 2, have a lifelong disease and will need ongoing follow-up and re-assessment for both anthropometric and clinical components of the diagnosis. For example, a current diagnosis of Obesity Stage 0 does not assure the perpetual absence of complications; these patients may convert to Stage 1 or 2 in the future, indicating the need for more aggressive weight-loss therapy. Similarly patients who are Overweight with no complications are at risk of future weight gain in our obesogenic environment and thus require lifestyle modifications and ongoing follow-up.
